Jonah F Byrne, Colm Healy, Melanie Föcking, Subash Raj Susai, David Mongan, Kieran Wynne, Eleftheria Kodosaki, Meike Heurich, Lieuwe de Haan, Ian B Hickie, Stefan Smesny, Andrew Thompson, Connie Markulev, Alison Ruth Young, Miriam R Schäfer, Anita Riecher-Rössler, Nilufar Mossaheb, Gregor Berger, Monika Schlögelhofer, Merete Nordentoft, Eric Y H Chen, Swapna Verma, Dorien H Nieman, Scott W Woods, Barbara A Cornblatt, William S Stone, Daniel H Mathalon, Carrie E Bearden, Kristin S Cadenhead, Jean Addington, Elaine F Walker, Tyrone D Cannon, Mary Cannon, Pat McGorry, Paul Amminger, Gerard Cagney, Barnaby Nelson, Clark Jeffries, Diana Perkins, David R Cotter
Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754)...
January 19, 2024: Schizophrenia Bulletin